SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
JOIN US ON
HME-forum.com
Join us online for these live, interactive,
expert-led broadcasts.
Register your interest at:
www.HME-forum.com
Please scan here
to register for
the upcoming
webinars
Please note that all events are only open to healthcare professionals
Registration prior to the live event is required in order to
access both the live and archived broadcasts.
Depending on your country, you may not have access to HME Forum.
Registered participants will also be
able to view archived versions of the
broadcasts following the live events.
With the support of Janssen Pharmaceutical
Companies of Johnson & Johnson in EMEA
Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse, Belgium
EM-41544
Date of Preparation: September 2020
Copyright © 2020 Janssen Pharmaceutica NV
Christian Buske
Germany
Michel Delforge
Belgium
Paolo Ghia
Italy